Alemtuzumab-based reduced-intensity conditioning for XIAP deficiency

被引：1
|
作者：
Kobushi, Hirokazu [1 ]
Umeda, Katsutsugu [1 ,4 ]
Hiejima, Eitaro [1 ]
Kato, Kentaro [1 ]
Sugimoto, Mayumi [2 ]
Kanegane, Hirokazu [3 ]
Takita, Junko [1 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan
[2] Tokushima Univ, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan
[3] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Child Hlth & Dept, Tokyo, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Pediat, 54 Kawahara Cho, Shogoin, Sakyo ku, Kyoto 6068507, Japan
来源：
PEDIATRICS INTERNATIONAL | 2023年 / 65卷 / 01期
关键词：
alemtuzumab; allogenic hematopoietic cell transplantation; mixed chimerism; XIAP deficiency; HEMATOPOIETIC-CELL TRANSPLANTATION;
D O I：
10.1111/ped.15576
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation
    I Avivi
    S Chakrabarti
    P Kottaridis
    C Kyriaku
    A Dogan
    D W Milligan
    D Linch
    A H Goldstone
    S Mackinnon
    Bone Marrow Transplantation, 2004, 34 : 137 - 142
  • [2] Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation
    Avivi, I
    Chakrabarti, S
    Kottaridis, P
    Kyriaku, C
    Dogan, A
    Milligan, DW
    Linch, D
    Goldstone, AH
    Mackinnon, S
    BONE MARROW TRANSPLANTATION, 2004, 34 (02) : 137 - 142
  • [3] A CASE OF UNRELATED BONE MARROW TRANSPLANTATION WITH ALEMTUZUMAB-BASED CONDITIONING REGIMEN FOR XIAP DEFICIENCY
    Kobushi, Hirokazu
    Umeda, Katsutsugu
    Hiejima, Eitaro
    Saida, Satoshi
    Kato, Itaru
    Hiramatsu, Hidefumi
    Adachi, Souichi
    Watanabe, Hiroyoshi
    Kanegane, Hirokazu
    Takita, Junko
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [4] Mixed Chimerism and Graft Loss in Pediatric Recipients of an Alemtuzumab-Based Reduced-Intensity Conditioning Regimen for Nonmalignant Disease
    Oshrine, Benjamin
    Olson, Timothy
    Bunin, Nancy
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S84 - S84
  • [5] Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia - A Single-Institution Experience
    Ramasamy, Karthik
    Mahmood, Shameem
    Lim, ZiYi
    Corderoy, Sophie
    Devereux, Stephen
    Mufti, Ghulam J.
    Pagliuca, Antonio
    Schey, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (02): : 242 - 245
  • [6] Mixed Chimerism and Graft Loss in Pediatric Recipients of an Alemtuzumab-Based Reduced-Intensity Conditioning Regimen for Non-Malignant Disease
    Oshrine, Benjamin R.
    Olson, Timothy S.
    Bunin, Nancy
    PEDIATRIC BLOOD & CANCER, 2014, 61 (10) : 1852 - 1859
  • [7] Early cytomegalovirus reactivation is associated with a poorer outcome after an alemtuzumab-based reduced-intensity conditioning allogeneic stem cell transplant
    Noriega, V.
    Cutino-Moguel, T.
    Zuckerman, M.
    Potter, V.
    Barabino, L.
    Raj, K.
    McLornan, D.
    de Lavallade, H.
    Devereux, S.
    Marsh, J.
    Sudhanva, M.
    Mufti, G.
    Pagliuca, A.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S299 - S300
  • [8] Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT
    C K Brierley
    T J Littlewood
    A J Peniket
    R Gregg
    J Ward
    A Clark
    A Parker
    R Malladi
    P Medd
    Bone Marrow Transplantation, 2015, 50 : 931 - 938
  • [9] Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT
    Brierley, C. K.
    Littlewood, T. J.
    Peniket, A. J.
    Gregg, R.
    Ward, J.
    Clark, A.
    Parker, A.
    Malladi, R.
    Medd, P.
    BONE MARROW TRANSPLANTATION, 2015, 50 (07) : 931 - 938
  • [10] Successful Allogeneic Hematopoietic Stem Cell Transplantation in XIAP Deficiency Using Reduced-Intensity Conditioning
    Chellapandian, Deepak
    Krueger, Joerg
    Schechter, Tal
    Gassas, Adam
    Weitzman, Sheila
    Naqvi, Ahmed
    Ali, Muhammad
    PEDIATRIC BLOOD & CANCER, 2016, 63 (02) : 355 - 357
12345